title: Age-dependent eradication of Helicobacter pylori in Japanese patients.
abstract: OBJECTIVE
  To determine the general risk factors affecting the failure rate of first-line eradication therapy in Japanese patients with Helicobacter pylori (H. pylori) infection.
  
  
  METHODS
  The present study enrolled 253 patients who had an H. pylori infection, underwent gastro-endoscopy, and were treated with H. pylori eradication therapy. Eradication therapy consisted of 30 mg lansoprazole plus 750 mg amoxicillin and 400 mg clarithromycin twice daily for 7 d. All of the patients underwent a 13C urea breath test at least 1 mo after the completion of eradication therapy. The current study investigated the independent factors associated with successful H. pylori eradication using a multiple logistic regression analysis.
  
  
  RESULTS
  The overall success rate in the patients was 85.8%. Among the general factors examined in the multivariate analyses, only having an age less than 50 years was found to be significantly associated with a poor response to H. pylori eradication. Moreover, side effects were the only clinical factors in the patients who were under 50 years of age that significantly influenced the poor response to H. pylori eradication.
  
  
  CONCLUSIONS
  H. pylori-positive elderly patients should undergo eradication therapy. In addition, it is necessary to improve H. pylori eradication therapy in younger patients.
authors.affiliation: Department of Gastroenterology and Hepatology, Shinko Hospital, 1-4-47 Wakihama-cho, Chuo-ku, Kobe, Hyogo 651-0072, Japan. m8583jp@yahoo.co.jp
authors.forename: Satoshi
authors.initials: S
authors.lastname: Mamori
authors.forename: Akihiro
authors.initials: A
authors.lastname: Higashida
authors.forename: Fumiaki
authors.initials: F
authors.lastname: Kawara
authors.forename: Katsuhiro
authors.initials: K
authors.lastname: Ohnishi
authors.forename: Akihiko
authors.initials: A
authors.lastname: Takeda
authors.forename: Eri
authors.initials: E
authors.lastname: Senda
authors.forename: Cho
authors.initials: C
authors.lastname: Ashida
authors.forename: Hajime
authors.initials: H
authors.lastname: Yamada
mesh_terms: D053799:2-Pyridinylmethylsulfinylbenzimidazoles / Q000627:therapeutic use; D000328:Adult; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000502:physiology*; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D017291:Clarithromycin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000208:ethnology / Q000503:physiopathology*; D016480:Helicobacter pylori; D006801:Humans; D007564:Japan; D064747:Lansoprazole; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D017211:Treatment Failure
chemical_list: D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000900:Anti-Bacterial Agents; D064747:Lansoprazole; D000658:Amoxicillin; D017291:Clarithromycin
references.citation: Ann Intern Med. 2007 Oct 16;147(8):553-62
references.pmid: 17938394
references.citation: Helicobacter. 2006 Dec;11(6):562-8
references.pmid: 17083378
references.citation: World J Gastroenterol. 2008 Sep 21;14(35):5385-402
references.pmid: 18803350
references.citation: World J Gastroenterol. 2005 Dec 21;11(47):7520-4
references.pmid: 16437727
references.citation: Aliment Pharmacol Ther. 1999 Aug;13(8):1047-55
references.pmid: 10468680
references.citation: Am J Gastroenterol. 1999 Jul;94(7):1751-9
references.pmid: 10406231
references.citation: Am J Gastroenterol. 2005 Aug;100(8):1696-701
references.pmid: 16086704
references.citation: Aliment Pharmacol Ther. 2002 Jul;16(7):1269-75
references.pmid: 12144576
references.citation: Am J Gastroenterol. 2000 Dec;95(12):3393-8
references.pmid: 11151867
references.citation: Helicobacter. 1997 Dec;2(4):185-7
references.pmid: 9421121
references.citation: Drugs. 1999 Jun;57(6):905-20
references.pmid: 10400404
references.citation: N Engl J Med. 2002 Oct 10;347(15):1175-86
references.pmid: 12374879
references.citation: Aliment Pharmacol Ther. 2002 Feb;16(2):167-80
references.pmid: 11860399
references.citation: Helicobacter. 2007 Nov;12 Suppl 2:50-8
references.pmid: 17991177
references.citation: Aliment Pharmacol Ther. 2000 Oct;14(10):1319-28
references.pmid: 11012477
references.citation: Am J Gastroenterol. 1998 Sep;93(9):1432-5
references.pmid: 9732920
references.citation: Am J Gastroenterol. 2005 Sep;100(9):1935-40
references.pmid: 16128936
references.citation: Aliment Pharmacol Ther. 2003 Jun 1;17(11):1381-7
references.pmid: 12786632
references.citation: Aliment Pharmacol Ther. 2004 Jul 1;20(1):99-107
references.pmid: 15225176
references.citation: Dig Dis Sci. 2000 Jan;45(1):68-76
references.pmid: 10695616
references.citation: Am J Gastroenterol. 1998 Nov;93(11):2106-12
references.pmid: 9820381
references.citation: Am J Gastroenterol. 1998 Dec;93(12):2330-8
references.pmid: 9860388
references.citation: Gut. 2004 Sep;53(9):1374-84
references.pmid: 15306603
references.citation: Gut. 2007 Jun;56(6):772-81
references.pmid: 17170018
references.citation: Aliment Pharmacol Ther. 2003 Apr;17(8):1065-74
references.pmid: 12694089
references.citation: Best Pract Res Clin Gastroenterol. 2004;18 Suppl:73-81
references.pmid: 15588798